Evaluating the role of the genetic variations of PTPN22, NFkB1 and FcGRIIIA genes in inflammatory bowel disease: A meta-analysis

Inflammatory Bowel Diseases

Volumn 13, Issue 10, 2007, Pages 1212-1219

  Latiano, Anna ^a   Palmieri, Orazio ^a   Valvano, Maria Rosa ^a   Bossa, Fabrizio ^a   Latiano, Tiziana ^a   Corritore, Giuseppe ^a   DeSanto, Ermelinda ^a   Andriulli, Angelo ^a   Annese, Vito ^a  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

Author keywords

CARD15; Crohn's disease; FcGRIIIA; Genotype phenotype; Inflammatory bowel disease; NFkB1; PTPN22; Ulcerative colitis

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; CHILD; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE PREDISPOSITION; ENTERITIS; FCGR111A GENE; FEMALE; GENE; GENE FREQUENCY; GENE FUNCTION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; NKFB1 GENE; PHENOTYPE; PRIORITY JOURNAL; PTPN22 GENE; RISK ASSESSMENT; ULCERATIVE COLITIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ALLELES; CHILD; CHILD, PRESCHOOL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DNA; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; NF-KAPPA B P50 SUBUNIT; POLYMERASE CHAIN REACTION; POLYMORPHISM, GENETIC; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 22; RECEPTORS, IGG;

EID: 35348951109     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20185     Document Type: Article

References (47)

1. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36:476-480.
2. Schreiber S, Rosenstiel P, Albrecht M, et al. Genetics of Crohn's disease, an archetypal inflammatory barrier disease. Nat Rev Genet. 2005;6:376-388.
3. Matthew CG, Lewis CM. Genetics of inflammatory bowel disease: progress and prospects. Hum Mol Genet. 2004;13:R161-168.
4. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521-533.
5. Hugot JP, Chamaillard M, Zouali H, et al. Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn's disease. Nature. 2001;411:599-603.
6. Ogura Y, Bonen DK, Inohara N, et al. A frameshift mutation in NOD2 associated with susceptibility to Crohn's disease. Nature. 2001;411:603-606.
7. Vermeire S, Rutgeerts P. Current status of genetics research in inflammatory bowel disease (IBD) [Review]. Genes Immun. 2005;6:637-645.
8. Trinh TT, Rioux JD. Understanding association and causality in the genetic studies on inflammatory bowel disease [Editorial]. Gastroenterology. 2005;129:2106-2110.
9. Stoll M, Corneliussen B, Costello CM, et al. Genetic variation in DLG5 is associated with inflammatory bowel disease. Nat Genet. 2004;36:476-480.
10. Peltekova VD, Wintle RF, Rubin LA, et al. Functional variants of OCTN cation transporter genes are associated with Crohn's disease. Nat Genet. 2004;36:471-475.
11. Duerr RH, Taylor KD, Brant SR, et al. A genome-wide association study identifies IL23R as an inflammatory bowel disease gene. Science. 2006;55:1820-1821.
12. Cho JH, Nicolae DL, Gold LH, et al. Identification of novel susceptibility loci for inflammatory bowel disease on chromosomes 1p, 3q, and 4q: evidence for epistasis between 1p and IBD1. Proc Natl Acad Sci U S A. 1998;95:7502-7507.
13. van Heel DA, Fisher SA, Kirby A, et al. Genome scan meta-analysis group of the IBD international genetics consortium. Inflammatory bowel disease susceptibility loci defined by genome scan meta-analysis of 1952 affected relative pairs. Hum Mol Genet. 2004;13:763-770.
14. Steer S, Lad B, Grumley JA, et al. Association of R602W in a protein tyrosine phosphatase gene with a high risk of rheumatoid arthritis in a British population: evidence for an early onset/disease severity effect. Arthritis Rheum. 2005;52:358-360.
15. Siminovitch KA. PTPN22 and autoimmune disease. Nat Genet. 2004;36:1248-1249.
16. Lindsey A, Criswell LA, Pfeiffer KA, et al. Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. Am J Hum Genet. 2005;76:561-571.
17. Bottini N, Musumeci L, Alonso A, et al. A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes. Nat Genet. 2004;36:337-338.
18. Smyth D, Cooper JD, Collins JE, et al. Replication of an association between the lymphoid tyrosine phosphatase locus (LYP/PTPN22) with type 1 diabetes, and evidence for its role as a general autoimmunity locus. Diabetes. 2004;53:3020-3023.
19. Kyogoku C, Langefeld CD, Ortmann WA, et al. Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. Am J Hum Genet. 2004;75:504-507.
20. Viken MK, Amundsen SS, Kvien TK, et al. Association analysis of the 1858C>T polymorphism in the PTPN22 gene in juvenile idiopathic arthritis and other autoimmune diseases. Genes Immun. 2005;6:271-273.
21. Prescott NJ, Fisher SA, Onnie C, et al. A general autoimmunity gene (PTPN22) is not associated with inflammatory bowel disease in a British population. Tissue Antigens. 2005;66:318-320.
22. Martin MC, Oliver J, Urcelay E, et al. The functional genetic variation in the PTPN22 gene has a negligible effect on the susceptibility to develop inflammatory bowel disease. Tissue Antigens. 2005;66:314-317.
23. Wagenleiter SE, Klein W, Griga T, et al. A case-control study of tyrosine phosphatase (PTPN22) confirms the lack of association with Crohn's disease. Int J Immunogenet. 2005;32:323-324.
24. van Oene M, Wintle RF, Liu X, et al. Association of the lymphoid tyrosine phosphatase R620W variant with rheumatoid arthritis, but not Crohn's disease, in Canadian populations. Arthritis Rheum. 2005;52:1993-1998.
25. De Jager PL, Sawcer S, Waliszewska A, et al. Evaluating the role of the 620W allele of protein tyrosine phosphatase PTPN22 in Crohn's disease and multiple sclerosis. Eur J Hum Genet. 2006;14:317-321.
26. Baldwin AS Jr. Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest. 2001;107:3-6.
27. Chen F, Castranova V, Shi X, et al. New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem. 1999;45:7-17.
28. Schreiber S. Activation of nuclear factor kappaB as a target for anti-inflammatory therapy. Gut. 1999;44:309-310.
29. Hampe J, Schreiber S, Shaw SH, et al. A genomewide analysis provides evidence for novel linkages in inflammatory bowel disease in a large European cohort. Am J Hum Genet. 1999;64:808-816.
30. Farmer MA, Sundberg JP, Bristol IJ, et al. A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice. Proc Natl Acad Sci U S A. 2001;98:13820-13825.
31. Karban AS, Okazaki T, Panhuysen CI, et al. Functional annotation of a novel NFKB1 promoter polymorphism that increases risk for ulcerative colitis. Hum Mol Genet. 2004;13:35-45.
32. Borm ME, van Bodegraven AA, Mulder CJ, et al. A NFKB1 promoter polymorphism is involved in susceptibility to ulcerative colitis. Int J Immunogenet. 2005;32:401-405.
33. Mirza MM, Fisher SA, Onnie C, et al. No association of the NFKB1 promoter polymorphism with ulcerative colitis in a British case control cohort. Gut. 2005;54:1205-1206.
34. Oliver J, Gomez-Garcia M, Paco L, et al. A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population. Inflamm Bowel Dis. 2005;11:576-579.
35. Glas J, Torok HP, Tonenchi L, et al. Role of the NFKB1 -94ins/delATTG promoter polymorphism in IBD and potential interactions with polymorphisms in the CARd15/NOD2, IKBL, and IL-1RN genes. Inflamm Bowel Dis. 2006;12:606-611.
36. Vermeire S, Rutgeerts P, Van Steen K, et al. Genome wide scan in a Flemish inflammatory bowel disease population: support for the IBD4 locus, population heterogeneity, and epistasis. Gut. 2004;53:980-986.
37. Dijstelbloem HM, Scheepers RH, Oost WW, et al. Fcgamma receptor polymorphisms in Wegener's granulomatosis: risk factors for disease relapse. Arthritis Rheum. 1999;42:1823-1827.
38. Myhr KM, Raknes G, Nyland H, et al. Immunoglobulin G Fc receptor (FcgammaR) IIA and IIIB polymorphisms related to disability in MS. Neurology. 1999;52:1771-1776.
39. Sullivan KE, Jawad AF, Piliero LM, et al. Analysis of polymorphisms affecting immune complex handling in systemic lupus erythematosus. Rheumatology (Oxf). 2003;42:446-452.
40. Morgan AW, Keyte VH, Babbage SJ, et al. FcgammaRIIIA-158 V and rheumatoid arthritis: a confirmation study. Rheumatology (Oxf). 2003;42:528-533.
41. Koene HR, Kleijer M, Algra J, et al. Fc gammaRIIIa-158 V/F polymorphism influences the binding of IgG by natural killer cell Fc gammaRIIIa, independently of the Fc gammaRIIIa-48L/R/H phenotype. Blood. 1997;90:1109-1114.
42. Wu J, Edberg JC, Redecha PB, et al. A novel polymorphism of FcgammaRIIIa (CD 16) alters receptor function and predisposes to autoimmune disease. J Clin Invest. 1997;100:1059-1070.
43. Louis E, El Ghoul Z, Vermeire S, et al. Association between polymorphism in IgG Fc receptor IIIa coding gene and biological response to infliximab in Crohn's disease. Aliment Pharmacol Ther. 12004;19:511-519.
44. Podolski DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-412.
45. Palmieri O. Latiano A, Valvano R, et al. MDR1 polymorphisms are not associated with inflammatory bowel disease and response to therapy in Italian patients. Aliment Pharmacol Ther. 2005;22:1129-1138.
46. Bonen DK, Cho JH. The genetics of inflammatory bowel disease. Gastroenterology. 2003;124:521-536.
47. Klein W, Tromm A, Folwaczny C, et al. A polymorphism of the NFKBIA gene is associated with Crohn's disease patients lacking a predisposing allele of the CARD15 gene. Int J Colorectal Dis. 2004;19:153-156.